Research and Markets: Global Cardiovascular Disorders Drug Pipeline Capsule - 2012

Research and Markets: Global Cardiovascular Disorders Drug Pipeline Capsule - 2012

<0> Research and MarketsLaura Wood, Senior Manager.U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Sector: </0>

() has announced the addition of the report to their offering.

Fore Pharma's latest report Global Cardiovascular Disorders Drug Pipeline Capsule - 2012' provides up-to-date information on key research and development activities in the global cardiovascular disorders drug market. It covers active pipeline molecules under development in various stages of clinical trials, preclinical research, and drug discovery for Acute Coronary Syndrome, Hypertension, Myocardial Infarction, Pulmonary Hypertension, Stroke, and Thrombosis.

This report helps executives track their competitor's pipeline molecules. The information presented in this report can be used for identifying partners, evaluating business opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

The report provides information on pipeline molecules by company, mechanism of action, stage (phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and drug discovery), and geography (North America, Europe, and Asia).

- Cardiovascular Disorders Drug Pipeline Insights

- Acute Coronary Syndrome Drug Pipeline Insights

- Hypertension Drug Pipeline Insights

- Myocardial Infarction Drug Pipeline Insights

- Pulmonary Hypertension Drug Pipeline Insights

- Stroke Drug Pipeline Insights

- Thrombosis Drug Pipeline Insights

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.